^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CEACAM5-targeted antibody-drug conjugate

    Related drugs:
    10d
    A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (clinicaltrials.gov)
    P3, N=1020, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • precemtabart tocentecan (M9140)
    19d
    MS202329_0010: Phase 1b/2 Study of Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Participants With Advanced Gastric Cancer (Substudy GC) (2024-517817-34-00)
    P1/2, N=45, Active, not recruiting, Merck Healthcare KGaA | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    HER-2 negative
    |
    precemtabart tocentecan (M9140)
    19d
    Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) (clinicaltrials.gov)
    P1/2, N=250, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Recruiting --> Active, not recruiting | Active, not recruiting --> Recruiting
    Enrollment closed • Enrollment open • Pan tumor
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    EGFR mutation • HER-2 negative • EGFR expression
    |
    precemtabart tocentecan (M9140)
    24d
    A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (clinicaltrials.gov)
    P3, N=1020, Not yet recruiting, EMD Serono Research & Development Institute, Inc.
    New P3 trial
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • precemtabart tocentecan (M9140)
    25d
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov)
    P1, N=200, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Feb 2027 --> Oct 2026 | Trial primary completion date: Feb 2027 --> Oct 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
    25d
    Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF wild-type
    |
    precemtabart tocentecan (M9140)
    25d
    A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (ChiCTR2600121742)
    P1, N=230, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Institute); Sun Yat-sen University Cancer
    New P1 trial • First-in-human
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • Avzivi (bevacizumab-tnjn)
    26d
    A Study of KIVU-305 in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=76, Not yet recruiting, Kivu Bioscience Inc.
    New P1 trial • First-in-human
    1m
    SGNCEA5C-001: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=914, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Suspended --> Recruiting | N=175 --> 914
    Enrollment open • Enrollment change
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    2ms
    SGNCEA5C-001: A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=165, Suspended, Seagen, a wholly owned subsidiary of Pfizer | Recruiting --> Suspended
    Trial suspension
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    3ms
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov)
    P1, N=200, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Aug 2026 --> Feb 2027 | Trial primary completion date: Aug 2026 --> Feb 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
    3ms
    A Study of BG-C477 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=310, Recruiting, BeOne Medicines | N=21 --> 310 | Trial completion date: Oct 2028 --> Dec 2027 | Trial primary completion date: Oct 2028 --> Dec 2027
    Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    Tevimbra (tislelizumab-jsgr)